Balancing Act Breast Cancer Segment Airs on
Lifetime Television on Oct. 14 and 21
Julie Megee, a Wrentham resident and breast cancer survivor,
will appear on The Balancing Act® airing on Lifetime Television in
October, National Breast Cancer Awareness Month. In conjunction
with the educational segment about breast cancer, Ms. Megee is
sponsoring a fundraiser for Breastcancer.org at Perceptions Hair
Studio, which she owns and operates in Norton, Mass.
Breast cancer survivor from Wrentham,
Mass. and Norton, Mass. business owner appears on The Balancing Act
airing on Lifetime Television to discuss breast cancer treatment
and tamoxifen citrate, Soltamox. (Photo: Business Wire)
DARA BioSciences, Inc. (NASDAQ: DARA), a Raleigh, N.C.-based
oncology supportive care pharmaceutical company dedicated to
providing health care professionals a synergistic portfolio of
medicines to help cancer patients adhere to their therapy and
manage side effects arising from their cancer treatment, sponsored
The Balancing Act® segment. DARA has pledged to match money raised
for Breastcancer.org by Ms. Megee.
The segment on The Balancing Act® airs Oct. 14 and 21 at 7 a.m.
EDT during Breast Cancer Awareness Month.
Ms. Megee’s breast cancer story is important because it
underlies the importance of early diagnosis and treatment options.
After discovering a lump in her breast during a self-exam in early
2013, she quickly scheduled a doctor’s appointment, underwent a
lumpectomy and radiation therapy, and is now taking Soltamox®
(tamoxifen citrate) to prevent recurrence of the disease. Soltamox®
is an oral liquid form of the commonly used medication tamoxifen,
until recently available in tablet form only.
“I have always had difficulty taking any type of tablet
medication, so I asked my oncologist if there was an alternative to
the tamoxifen tablet because I couldn’t imagine taking a tablet
every day for at least five years,” Ms. Megee said. Her doctor
prescribed Soltamox® (tamoxifen citrate) instead, the only liquid
formulation of tamoxifen available. DARA BioSciences markets
Soltamox® in the United States.
As part of her fundraising effort to support Breastcancer.org,
Ms. Megee and her team at Perceptions Hair Studio will donate $5
for every new client appointment. Breastcancer.org is a leading
online resource for breast health and breast cancer information. “I
am grateful for the opportunity to support Breastcancer.org which
does so much to support women with breast cancer like me,” Ms.
Megee said. To donate and learn more, visit their fundraising
page.
“We are grateful to Julie and her co-workers for supporting our
efforts to provide the most reliable, complete and up-to-date
information about breast cancer to help women and their loved ones
make informed decisions for their lives,” said Rita Lusen, vice
president of corporate partnerships and marketing of
Breastcancer.org. “Thank you and congratulations to Julie, her
team, DARA and The Balancing Act® on producing this timely
educational segment about breast cancer and cancer supportive
care.”
Ms. Megee joins Nancy Peacock, MD, Tennessee Oncology medical
oncologist and breast cancer specialist at St. Thomas Midtown
Hospital in Nashville, Tenn., and The Balancing Act® host Danielle
Knox in studio and discuss oncology supportive care issues,
including the importance of patient compliance to tamoxifen
therapy, and how Soltamox® (tamoxifen citrate) oral solution may
help improve patient compliance. The segment also touches on side
effects of cancer treatment, including skin burns and oral
mucositis caused by radiation treatment and chemotherapy. DARA
markets Gelclair®, an oral rinse gel for relief of oral mucositis
pain, and Bionect®, a topical treatment for skin irritation and
burns, in the US oncology/radiology markets. Dr. Peacock and Julie
also discuss the important role of patient educational resources
such as Breastcancer.org.
“We are pleased to partner with The Balancing Act® to produce
this educational segment about breast cancer treatment and support,
and appreciate The Balancing Act’s commitment to breast cancer
education and programming during Breast Cancer Awareness Month”
said David J. Drutz, MD, DARA's chief executive officer and chief
medical officer. “We are grateful to Dr. Peacock and Ms. Megee for
sharing their experiences on national television, so that others
may learn from their insights and knowledge.”
According to recently published National Comprehensive Cancer
Network (NCCN) Guidelines (Version 3.2013), tamoxifen is the most
firmly established adjuvant endocrine therapy for both
premenopausal and postmenopausal women with ER-positive breast
cancer. Tamoxifen is usually administered as 20mg daily for five
years. The American Society of Clinical Oncology (ASCO) Clinical
Practice Guidelines published on July 8, 2013, recommends that in
women at increased risk of breast cancer age 35 or older, tamoxifen
prophylaxis (20mg per day for five years) should be discussed as an
option to reduce the risk of estrogen receptor (ER) positive breast
cancer. Soltamox® (tamoxifen citrate) oral solution is
bioequivalent to tamoxifen and is prescribed for the same
indications. Please see Soltamox® Important Safety Information and
the Black Box Warning at the end of this press release. For
additional information and a copy of the complete Prescribing
Information visit www.soltamox.com.
About DARA BioSciences
DARA BioSciences Inc. is an oncology supportive care
pharmaceutical company dedicated to providing healthcare
professionals a synergistic portfolio of medicines to help cancer
patients adhere to their therapy and manage side effects arising
from their cancer treatment.
DARA holds exclusive U.S. marketing rights to Soltamox®
(tamoxifen citrate) oral solution, the only liquid form of
tamoxifen, used for the treatment and prevention of breast cancer.
Soltamox® offers a choice to patients who prefer or need a liquid
form of tamoxifen. Gelclair® is an alcohol-free bioadherent oral
rinse gel for rapid and effective relief of pain associated with
oral mucositis caused by chemotherapy and radiation treatment. DARA
licensed the U.S. rights to Soltamox® from UK-based Rosemont
Pharmaceuticals, Ltd., and Gelclair® from the Helsinn Group in
Switzerland. Under an agreement with Innocutis, DARA also markets
Bionect (hyaluronic acid sodium salt, 0.2%), a topical treatment
for skin irritation and burns associated with radiation therapy, in
US oncology/radiology markets.
DARA is focused on expanding its portfolio of oncology
supportive care products in the US, via in-licensing and/or
partnering of complementary late-stage and approved products. In
addition, the company wishes to identify a strategic partner for
the clinical development of KRN5500, currently in Phase 2 for the
treatment of chronic, treatment refractory, chemotherapy induced
peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a
Fast Track Drug, and DARA is seeking orphan status for the
treatment of CCIPN.
About Breastcancer.org
Breastcancer.org is the #1 online resource for breast health and
breast cancer information and support, with more than 6,000 pages
of expert-reviewed information and a robust, dynamic peer support
community. A nonprofit organization, Breastcancer.org receives more
than 12 million visits each year.
About The Balancing
Act® on Lifetime Television
Now in its 6th year, The Balancing Act® continues to empower
women in all aspects of their lives. The mission at The Balancing
Act® is simple -- the show strives to help today’s modern woman
balance it all by bringing them exceptional solutions to everyday
problems. Entertaining, educational and trusted by women, viewers
can watch America’s premier morning show The Balancing Act® weekday
mornings on Lifetime television at 7 a.m. (ET/PT).
For additional information or to view a segment visit
www.thebalancingact.com.
IMPORTANT SAFETY
INFORMATION
Tamoxifen citrate is contraindicated in patients with known
hypersensitivity and also in women who require concomitant
coumarin-type anticoagulant therapy or in women with a history of
deep vein thrombosis or pulmonary embolus. As with other additive
hormonal therapy (estrogens and androgens), hypercalcemia has been
reported in some breast cancer patients with bone metastases within
a few weeks of starting treatment with tamoxifen. If hypercalcemia
does occur, appropriate measures should be taken and, if severe,
tamoxifen should be discontinued. There is evidence of an increased
incidence of thromboembolic events, including deep vein thrombosis
and pulmonary embolism, during tamoxifen therapy. When tamoxifen is
coadministered with chemotherapy, there may be a further increase
in the incidence of thromboembolic effects. Adverse reactions to
tamoxifen are relatively mild and rarely severe enough to require
discontinuation of treatment in breast cancer patients.
WARNING
In Women with Ductal Carcinoma in Situ (DCIS) and Women at High
Risk for Breast Cancer Serious and life-threatening events were
associated with tamoxifen in the risk reduction setting (women at
high risk for cancer and women with DCIS) include uterine
malignancies, stroke and pulmonary embolism. (see CLINICAL
PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer
Incidence In High Risk Women). Health care providers should discuss
the potential benefits versus the potential risks of these serious
events with women at high risk of breast cancer and women with DCIS
considering tamoxifen to reduce their risk of developing breast
cancer. The benefits of tamoxifen outweigh its risks in women
already diagnosed with breast cancer.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call
1-855-273 0468
Safe Harbor Statement
All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements
are subject to factors that could cause actual results to differ
materially for DARA from those projected. Important factors that
could cause actual results to differ materially from the
expectations described in these forward-looking statements are set
forth under the caption “Risk Factors” in DARA’s most recent Annual
Report on Form 10-K, filed with the SEC on March 28, 2013. Those
factors include risks and uncertainties relating to DARA's ability
to timely commercialize and generate revenues or profits from
Bionect®, Soltamox®, Gelclair® or other products given that DARA
only recently hired its initial sales force and DARA's lack of
history as a revenue-generating company, FDA and other regulatory
risks relating to DARA's ability to market Bionect, Soltamox,
Gelclair or other products in the U.S. or elsewhere, DARA's ability
to develop and bring new products to market as anticipated, DARA's
current cash position and its need to raise additional capital in
order to be able to continue to fund its operations, the current
regulatory environment in which DARA develops and sells its
products, the market acceptance of those products, dependence on
partners, successful performance under collaborative and other
commercial agreements, competition, the strength of DARA's
intellectual property and the intellectual property of others, the
potential delisting of DARA's common stock from the NASDAQ Capital
Market, risks and uncertainties relating to DARA's ability to
successfully integrate Oncogenerix and other risk factors
identified in the documents DARA has filed, or will file, with the
Securities and Exchange Commission ("SEC"). Copies of DARA's
filings with the SEC may be obtained from the SEC Internet site at
http://www.sec.gov. DARA expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in DARA's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are
based. DARA BioSciences and the DARA logo are trademarks of DARA
BioSciences, Inc.
Keywords: Balancing Act, DARA BioSciences, tamoxifen, liquid
tamoxifen, Soltamox, ductal carcinoma in situ, node-positive breast
cancer, Tennessee Oncology, St. Thomas Midtown Hospital, breast
cancer, estrogen receptor positive, liquid formulation.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20131007005084/en/
Media Contacts:LaVoie GroupDavid Connolly or
Samantha Stenbeck,
617-374-8800dconnolly@lavoiegroup.comsstenbeck@lavoiegroup.comorCorporate
Contact:DARA BioSciencesJenene Thomas,
908-938-1475jthomas@darabio.com
(MM) (NASDAQ:DARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:DARA)
Historical Stock Chart
From Jul 2023 to Jul 2024